Contineum Therapeutics (CTNM) had its price target raised by Robert W. Baird from $14.00 to $20.00. They now have an "outperform" rating on the stock.
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones [Yahoo! Finance]
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus [Yahoo! Finance]